Medivation Inc (MDVN)

80.30
0.06 0.08
NASDAQ : Health Care
Prev Close 80.24
Open 80.24
Day Low/High 80.21 / 80.33
52 Wk Low/High 26.41 / 80.67
Volume 7.16M
Avg Volume 3.16M
Exchange NASDAQ
Shares Outstanding 165.93M
Market Cap 13.31B
EPS 1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Portfolio Manager: Is Pfizer Acquiring Too Quickly?

Portfolio Manager: Is Pfizer Acquiring Too Quickly?

Pfizer's second acquisition this week could add risk. Some retailers attract portfolio managers.

Pfizer Is Buying a Portion of AstraZeneca's Antibiotics Business

Pfizer Is Buying a Portion of AstraZeneca's Antibiotics Business

Pfizer is making another acquisition.

Why Pfizer's Latest Deal Could Send Its Shares Soaring

Why Pfizer's Latest Deal Could Send Its Shares Soaring

The acquisition of Medivation gives the pharma giant a top-selling oncology drug and an immediate profit boost.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

Pfizer buys antibiotics business from AstraZeneca; Tesla unveils Model S version that can go 300 miles on a single charge; U.S. stock futures rise slightly.

INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Regarding Whether The Sale Of Medivation, Inc. To Pfizer Inc. Is Fair To Shareholders

INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Regarding Whether The Sale Of Medivation, Inc. To Pfizer Inc. Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Medivation, Inc.

Medivation (MDVN) Stock Downgraded After Pfizer Deal

Medivation (MDVN) Stock Downgraded After Pfizer Deal

Medivation's (MDVN) stock rating was cut by several firms on Tuesday morning after the company agreed to be acquired by Pfizer (PFE) for $14 billion yesterday.

Jim Cramer's 'Mad Money' Recap: I'm Watching Best Buy, PVH, Yellen This Week

Jim Cramer's 'Mad Money' Recap: I'm Watching Best Buy, PVH, Yellen This Week

Earnings season is far from over, Cramer says, and the Fed chief gives a major speech Friday.

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of...

Market Keeps Chasing Its Own Tail

Stocks travel a good distance just to end up nowhere.

Stocks Waver as Investors Wait for Fed Clarity

Stocks Waver as Investors Wait for Fed Clarity

Wall Street will get more clues on the Fed's rate hike plans later this week, but uncertainty over what they might be led to jittery trading on Monday.

Stocks Struggle for Direction as Jackson Hole Conference Looms

Stocks Struggle for Direction as Jackson Hole Conference Looms

Stocks fluctuate Monday afternoon as a selloff in crude oil hits the energy sector and Federal Reserve speeches at the end of the week leave investors wary.

Medivation, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Merger With Pfizer Inc.

Medivation, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Merger With Pfizer Inc.

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Medivation, Inc.

Medivation Scores Premium in Sale to Pfizer

Medivation Scores Premium in Sale to Pfizer

Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.

Cramer: A Bunch of Semis Are Ripe for the Picking

Cramer: A Bunch of Semis Are Ripe for the Picking

That's the hot spot in M&A right now.

Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.

Crude Selloff, Health Care Rally Split Wall Street

Crude Selloff, Health Care Rally Split Wall Street

Stocks fluctuate on Monday as doubts over a production freeze agreement from major oil-producing countries snapped crude oil's recent rally.

Pfizer to Pick Up Medivation in All-Cash Deal

PFE is trading up on the announcement, and the deal should add to earnings in 2017.

Facebook Stands Out and FormFactor Has a Good Start

Facebook Stands Out and FormFactor Has a Good Start

Overall, this is still a good environment for stock picking.

More Squawk from Jim Cramer: Pfizer Buys Medivation (MDVN) for $14 Billion

More Squawk from Jim Cramer: Pfizer Buys Medivation (MDVN) for $14 Billion

The deal is 'very healthy' for the biopharma group, according to TheStreet's Jim Cramer.

Pfizer Is Buying Medivation for $14 Billion

Pfizer Is Buying Medivation for $14 Billion

Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.

Stock Futures Slide as Crude's Winning Streak Is Snapped

Stock Futures Slide as Crude's Winning Streak Is Snapped

Stock futures move lower on Monday as doubts over a production freeze agreement from major oil-producing countries leave crude oil in the lurch.

Morning Movers: PFE, VRX, VIAB, FL, UA

Morning Movers: PFE, VRX, VIAB, FL, UA

Pfizer agrees to acquire Medivation while Citi puts Foot Locker and Under Armour on the back-to-school shopping list.

Pfizer Buys Medivation, the Crown Jewel in Cancer Therapy

Pfizer Buys Medivation, the Crown Jewel in Cancer Therapy

A potential blockbuster drug deal is reportedly in the works.

5 Things You Must Know Before the Market Opens Monday

5 Things You Must Know Before the Market Opens Monday

Pfizer finalizes a deal to buy cancer drugmaker Medivation; ChemChina gets U.S. approval for its takeover of Syngenta; Viacom CEO Philippe Dauman is ousted.

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.

Pfizer To Acquire Medivation

Pfizer To Acquire Medivation

Pfizer Inc. (NYSE:PFE) and Medivation, Inc.